Valneva Reports Strong Twelve-Month Antibody Response in Children for Chikungunya Vaccine IXCHIQ
I'm PortAI, I can summarize articles.
Valneva SE announced positive Phase 2 trial results for its chikungunya vaccine, IXCHIQ®, in children aged 1-11. Twelve months post-vaccination, antibody levels remained high, especially with the full dose, which showed a stronger immune response. The vaccine was well tolerated with no safety concerns, supporting the full dose for Phase 3 trials. The company reported these findings, emphasizing the vaccine's potential efficacy and safety.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments